Advertisement
Commentary Free access | 10.1172/JCI37787
1Research Center, Montreal Heart Institute, Faculty of Pharmacy, University de Montréal, Montreal, Quebec, Canada. 2Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
Address correspondence to: Wayne R. Giles, Faculty of Kinesiology, University of Calgary, 2500 University Drive NW, Calgary, Canada, T2N 1N4. Phone: (403) 220-5607; Fax: (403) 220-0448; E-mail: wgiles@ucalgary.ca.
Find articles by Fiset, C. in: JCI | PubMed | Google Scholar
1Research Center, Montreal Heart Institute, Faculty of Pharmacy, University de Montréal, Montreal, Quebec, Canada. 2Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
Address correspondence to: Wayne R. Giles, Faculty of Kinesiology, University of Calgary, 2500 University Drive NW, Calgary, Canada, T2N 1N4. Phone: (403) 220-5607; Fax: (403) 220-0448; E-mail: wgiles@ucalgary.ca.
Find articles by Giles, W. in: JCI | PubMed | Google Scholar
Published November 20, 2008 - More info
In human cardiomyopathy, anatomical abnormalities such as hypertrophy and fibrosis contribute to the risk of ventricular arrhythmias and sudden death. Here we have shown that increased myofilament Ca2+ sensitivity, also a common feature in both inherited and acquired human cardiomyopathies, created arrhythmia susceptibility in mice, even in the absence of anatomical abnormalities. In mice expressing troponin T mutants that cause hypertrophic cardiomyopathy in humans, the risk of developing ventricular tachycardia was directly proportional to the degree of Ca2+ sensitization caused by the troponin T mutation. Arrhythmia susceptibility was reproduced with the Ca2+-sensitizing agent EMD 57033 and prevented by myofilament Ca2+ desensitization with blebbistatin. Ca2+ sensitization markedly changed the shape of ventricular action potentials, resulting in shorter effective refractory periods, greater beat-to-beat variability of action potential durations, and increased dispersion of ventricular conduction velocities at fast heart rates. Together these effects created an arrhythmogenic substrate. Thus, myofilament Ca2+ sensitization represents a heretofore unrecognized arrhythmia mechanism. The protective effect of blebbistatin provides what we believe to be the first direct evidence that reduction of Ca2+ sensitivity in myofilaments is antiarrhythmic and might be beneficial to individuals with hypertrophic cardiomyopathy.
Franz Baudenbacher, Tilmann Schober, Jose Renato Pinto, Veniamin Y. Sidorov, Fredrick Hilliard, R. John Solaro, James D. Potter, Björn C. Knollmann
Mutations in contractile proteins in heart muscle can cause anatomical changes that result in cardiac arrhythmias and sudden cardiac death. However, a conundrum has existed because mutations in one such contractile protein, a so-called Ca2+ sensor troponin T (TnT), can promote ventricular rhythm disturbances even in the absence of hypertrophy or fibrosis. Thus, these mutations must enhance abnormal electrophysiological events via alternative means. In this issue of the JCI, Baudenbacher et al. report a novel mechanism to explain this puzzle (see the related article beginning on page 3893). They show that a selected TnT mutation in the adult mouse heart can markedly increase the sensitivity of cardiac muscle myofilaments to Ca2+ and enhance the susceptibility to arrhythmia, even in the absence of anatomical deformities. As these same mutations can cause some forms of arrhythmias in humans, these findings are of both basic and translational significance.
Cardiomyopathy is defined as a heterogeneous group of diseases of the myocardium that are associated with mechanical and/or electrical dysfunction (1, 2). Ventricular hypertrophy and fibrosis and/or inappropriate dilation in the absence of coronary disease, hypertension, valvular disease, or congenital heart disorders are commonly observed. In mammalian hearts, cardiomyopathies may be either inherited or acquired and often result in or are accompanied by disturbances in ventricular rhythms. The significant incidence of cardiomyopathy in the older and diabetic populations has lead to intensive research into the cellular and molecular causes of this syndrome.
These findings, however, have raised a fundamental question related to whether anatomical changes are a prerequisite or a consequence of the life-threatening rhythm disturbances observed in association with cardiomyopathies. One approach to solving this problem is based on application of genetic techniques that alter either the amount or the functional properties of the contractile proteins within the cardiac cell (myocyte). In particular, investigators have shown that alteration (mutation) of individual amino acids in the contractile protein that is the major Ca2+ sensor, troponin T (TnT), can lead to life-threatening rhythm disturbances in the absence of any detectable changes in myocyte structure or increase in fibroblasts within the heart (3, 4). Interestingly, however, this mutation results in the contractile elements responding to changes in intracellular Ca2+ in a way that reflects a sensitization or overall increased sensitivity to changes in intracellular Ca2+. This change is of fundamental significance to the heart, since, on a beat-by-beat basis, Ca2+ enters the cell through Ca2+ channels in the surface membrane, and this Ca2+ entry promotes rapid and large release of Ca2+ from the main intracellular store, the sarcoplasmic reticulum. This rapid increase in intracellular Ca2+ is detected by the Ca2+-sensitive protein TnT, which then undergoes a structural alteration to allow the contractile filaments actin and myosin to interact. This produces a cellular contraction and the heart beat.
A multidisciplinary study by Baudenbacher, Knollmann, and colleagues (3) in this issue of the JCI advances our present understanding of the pathophysiological basis for cardiomyopathy in the absence of cardiac anatomical abnormalities such as hypertrophy or fibrosis. In this study and previous work from this laboratory (4), a combination of pharmacologic and transgenic approaches, both in vitro and in vivo, were used to identify and characterize the electrophysiologic sequelae (e.g., ventricular tachycardia) associated with cardiomyopathy. Targeted mutations of individual amino acids within the main Ca2+ sensor, TnT, and in selected regions of sarcomere thin filament proteins are well known to result in alterations in their Ca2+ sensitivity (5, 6). It is noteworthy that selective changes of this kind can in fact result in either increased or decreased Ca2+ sensitivity (7), as well as significant changes in myocyte or tissue metabolism/energetics (8). The mutation that is the focus of the Baudenbacher et al. study (3) results in significantly increased Ca2+ sensitivity of the contractile myofilaments in the mouse heart. This increase in Ca2+ sensitivity, by as yet undefined mechanism(s), results in altered patterns of ventricular electrical activity. Specifically, there are changes in conduction velocity and the excitability of the ventricle, as demonstrated by its ability to react to applied stimuli (shortened effective refractory period). These changes combine to result in a markedly increased tendency for inducible tachyarrhythmias (clusters of abnormally rapid beating), following programmed stimulation or the application of the cardiac adrenergic stimulant isoproterenol. The authors also observed marked changes in cellular electrophysiology; the action potential shortened dramatically. All of these electrophysiological changes were reported to be closely mimicked by application of EMD 50733, a pharmacological agent that is considered to be a selective myofilament Ca2+ sensitizer (9). In addition, the incidence of ventricular rhythm disturbances was markedly reduced or eliminated by administration of the Ca2+ desensitizing compound blebbistatin, which prevents actin-myosin interactions (10, 11).
Selected mutations in TnT in the mouse ventricular myocyte can result in a cardiomyopathic syndrome, including hypertrophy and fibrosis as well as an increased tendency for ventricular rhythm disturbances and Ca2+-dependent changes in action potential morphology (4). Baudenbacher et al. (3) now demonstrate that the increased susceptibility to arrhythmia can be observed in the absence of any detectable cardiac hypertrophy or fibrosis. They report that the increased risk of ventricular tachycardia is directly proportional to the enhancement of Ca2+ sensitization caused by the selected TnT mutation.
It is very important, therefore, to consider in some detail the Ca2+ sensitivity findings reported in the current study (3). The authors report a significantly enhanced steady-state Ca2+sensitivity based on force measurements from chemically skinned ventricular trabeculae from adult mouse ventricles. One would expect that this change may alter overall Ca2+ buffering or homeostasis within each myocyte (12). As a consequence important changes in intracellular Ca2+ could take place during both the contractile (systolic) and the relaxation (diastolic) phases of ventricular function. Such changes in intracellular Ca2+ levels are known to have significant electrophysiological effects.
If Ca2+ levels were to increase, it would be expected that the predominant Ca2+ current in the mouse ventricle may decrease in size and turn off, or inactivate, more quickly (12). This would be consistent with the action potential data reported by Baudenbacher et al. (3), which demonstrated action potential shortening: a loss of the plateau and marked shortening of duration during early repolarization. Changes in intracellular Ca2+ concentration would also alter the transport of Ca2+ out of the cell by the so-called Na+/Ca2+ exchange mechanism (12), and this electrogenic transporter can alter ventricular excitability.
Experimental approaches applied in rat and mouse myocytes, in which genetic manipulations or pharmacological treatment have caused changes in contractile filament Ca2+ sensitivity, can also cause altered myocyte metabolism/energetics (8, 13). If these metabolic changes resulted in significant decreases in either the spatially averaged or localized levels of ATP, it would be reasonable to expect activation of ATP-sensitive K+ current and alteration of both the Na+/Ca2+ exchanger and the Na+/K+ pump. Previous work has demonstrated that the molecular transcripts responsible for generating ATP-sensitive K+ currents are expressed in the adult mouse ventricle and that either pharmacological or genetic alteration in this current can significantly alter the ventricular electrophysiological characteristics. These alterations can be either protective or proarrhythmic (14, 15).
Our groups (16) and others have shown that action potential shape changes similar to those described by Baudenbacher et al. (3) can dramatically alter the associated intracellular Ca2+ transient that triggers each cardiac contraction. Specifically, shortening the action potential decreases the Ca2+ influx carried by L-type Ca2+ channels. Since this Ca2+ influx is the “trigger” for Ca2+ release from the sarcoplasmic reticulum, the intracellular Ca2+ transient is decreased substantially by action potential shortening in the mammalian heart (17, 18). It is also known that this pattern of events differs significantly between myocytes from the right versus the left ventricle in the adult mouse heart (19). The decreased action potential duration reported by Baudenbacher et al. (3) would be predicted to result in a significant decrease in contractile strength or negative inotropic effect. This would be consistent with one of the principle features of pronounced cardiomyopathy.
The overall Ca2+ homeostasis (or buffering capacity in the adult ventricular myocyte) is modulated strongly by the myocyte resting membrane potential (20, 21). This is a consequence of the link between membrane potential and activity (voltage dependence) of Na+/Ca2+ exchange under physiological conditions. These fundamental electrophysiological principles and the recent report (22) of a strong link between membrane potential, Na+/Ca2+ exchange, and associated changes in action potential morphology and incidence of rhythm disturbances (in rabbit ventricle) are noteworthy. In fact, in a previous paper from the Knollmann group (4), changes in the inwardly rectifying background K+ current, IK1, which generates the mouse ventricular myocyte resting potential, were reported in myocytes from animals in which TnT mutations had been made. Neither the voltage sensitive dye methodology, nor the monophasic action potential records used by Baudenbacher et al. (3) are capable of detecting small (e.g., 10 mV) but significant changes in resting potential. It is also noteworthy that two of the major findings in the current study depend on the compounds EMD 57033 and blebbistatin being very selective, that is, without effect on any of the time- and voltage-dependent currents or background currents in the mouse ventricle.
The elegant, but also very complex, pattern of results reported by the Knollmann group (3, 4) need to be placed into both physiological and pathophysiological contexts. Systems biology approaches may be able to be used as an adjunct to address these integrative challenges. In fact, a comprehensive mathematical model for the action potential of the mouse ventricular myocyte has been developed by Bondarenko et al. (23). That is, systems of equations have been developed for each of the major ionic currents that underlie the mouse ventricle action potential, and these have been combined to yield useful mathematical simulations of the action potential and associated intracellular Ca2+ release and buffering.
This approach has been extended, e.g., by the Physiome Project, to provide computational platforms that are scalable (address problems at both subcellular and tissue levels) while also providing a framework for detailed considerations of the action potential, intracellular Ca2+ homeostasis, and excitation-contraction coupling (24). In silico representations of myocyte mechanical activity and myocardium metabolism, including detailed considerations of mitochondrial biochemistry and energetics, and possible linkages to myocyte Ca2+ homeostasis have also been developed (25, 26). These theoretical approaches may be helpful in integrating the main findings of the current study (3) with the extensive and diverse literature that must be accounted for.
At present, however, the challenge of defining the cellular mechanisms that underlie ventricular cardiomyopathy has been advanced by the work of Baudenbacher et al. (3), who have successfully separated primary changes in intracellular Ca2+ sensor mechanisms from the anatomical changes that develop later in the cardiomyopathic syndrome. These authors have also convincingly demonstrated the utility of a multidisciplinary approach to a major problem in contemporary molecular cardiology.
Experimental and theoretical work in the authors’ laboratories is supported by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. W.R. Giles holds a Medical Scientist Award from the Alberta Heritage Foundation for Medical Research. C. Fiset is a Research Scholar of the Fonds de la Recherche en Santé du Quebéc (FRSQ).
Address correspondence to: Wayne R. Giles, Faculty of Kinesiology, University of Calgary, 2500 University Drive NW, Calgary, Canada, T2N 1N4. Phone: (403) 220-5607; Fax: (403) 220-0448; E-mail: wgiles@ucalgary.ca.
Nonstandard abbreviations used: TnT, troponin T.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J. Clin. Invest.118:3845–3847 (2008). doi:10.1172/JCI37787.
See the related article at Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.